Purchase this article with an account.
Leonie C. van Dinten, Nicolien Pul, A. Frans van Nieuwpoort, Coby J. Out, Martine J. Jager, Peter J. van den Elsen; Uveal and Cutaneous Melanoma: Shared Expression Characteristics of Melanoma-Associated Antigens. Invest. Ophthalmol. Vis. Sci. 2005;46(1):24-30. https://doi.org/10.1167/iovs.04-0961.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
purpose. Downregulation of melanoma-associated antigens (MAAs), against which natural cytolytic T lymphocytes (CTLs) exist in humans, is one of the mechanisms that aids in evasion of immune surveillance. In view of putative re-expression strategies for MAAs during immunotherapy, this study was conducted to investigate MAA silencing in malignant melanoma.
methods. The expression of the MAA Melan-A/MART-1 was analyzed in 10 uveal and 10 cutaneous patient-derived melanoma cell lines by Western blot analysis and RT-PCR. Expression characteristics of four other MAAs—Tyr, Tyrp1, Dct, and gp100/Pmel17—were analyzed by RT-PCR. DNA methylation patterns at the Melan-A/MART-1 promoter region were investigated by methylation-sensitive restriction enzyme digestion and subsequent Southern blot analysis. Exogenous promoter activity was assessed in all 20 melanoma cell lines to correlate the DNA methylation patterns with Melan-A/MART-1 expression.
results. MAA expression was observed in 15 of the 20 melanoma cell lines. Furthermore, there is a direct correlation between DNA methylation patterns at the Melan-A/MART-1 promoter region, exogenous Melan-A/MART-1 promoter activity, and Melan-A/MART-1 protein expression. These data reveal the division of patient-derived melanoma cell lines into two distinct subsets, which are identical for both uveal and cutaneous tumor types.
conclusions. The authors propose a categorization of melanoma cell lines into two different panels based on shared MAA-expression characteristics: panel I, MAA-expressing cell lines, and panel II, MAA-deficient cell lines. This categorization can be used to obtain knowledge about the regulation of MAA-expression and for further research concerning MAA-based immunotherapy.
This PDF is available to Subscribers Only